Abstract: The present invention relates to a process of extracting native proteins from vegetable source materials such as oilseeds, legumes and grains. Native proteins mentioned in this invention are present in the source material in their non-denatured state, i.e. with their functional properties relevant to application in food industry like solubility preserved and not compromised by processing conditions. Source materials mentioned in the present invention are of vegetable origin and typically contain significant (>5% by weight) amounts of native oils and lipids. The invention further relates to a device for carrying out this process and to the native protein obtainable by the process of the invention.

Abstract: The present invention discloses an improved nanoemulsion comprising a uniform and discrete range of very small particle nano-sized diameters. This uniformity results in improved bioavailability of incorporated compounds (i.e., pharmaceuticals or nutraceuticals) as reflected in various pharmacokinetic parameters including, but not limited to, decreased Tmax, increased CmaX3 and increased AUC. The improved method of making these uniform nanoemulsions utilizes microfluidization which differs in both process and mechanics when compared to conventional milling and grinding techniques used to generate nanoparticulate compositions. Further, the improvement results, in part, from a novel step of mixing a substantially soluble compound into a heated dispersion medium. This is unlike current nanoparticulate composition methods that mix an insoluble compound with an unheated dispersion medium. Further, these nanoemulsions are observed to be bacterial-resistant and stable to extremes in both temperature and pH changes.

Abstract: The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair.

Abstract: An apparatus for mineralising a biological material includes an ultrasonic source, operable to generate an ultrasonic signal, an ultrasonic probe and one or more mineralising probes, operable to receive a mineralising agent. The mineralising agent is transferred from at least one mineralising probe to the biological material using the ultrasonic signal. Also disclosed are a mineralisation agent and a method of mineralising a biological material that includes the steps of: providing an ultrasound source, providing a mineralising agent, generating an ultrasonic signal from the ultrasound source, and applying the ultrasonic signal and the mineralising agent to the biological material separately, sequentially or simultaneously.

Abstract: A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, Omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides. The composition may optionally be further utilized for the prevention of hypercholesterolemia, bone (and teeth) mineral loss, treatment of mental health diseases, heart health, additional nutritional supplementation, and treatment of additional medical conditions.

Abstract: The present invention provides a ketogenic diet in the form of a sterile shelf stable ready to use formula, in particular a tube feed, comprising casein and dietary fiber.

Abstract: The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.

Abstract: This invention relates to the coagulation of protein containing nutritional compositions in the upper gastro-intestinal tract, more in particular in the stomach and provides a method for reducing suchcoagulation.

Abstract: This document provides methods and materials for providing teeth with a white appearance. For example, methods and materials for contacting teeth with one or more fluorescence emitting polypeptides (e.g., a blue fluorescent protein (BFP)) to provide the teeth with a whiter appearance are provided.

Abstract: The invention relates to peptides and, in particular, heptapeptides derived from milk casein ?s1 and having anxiolytic activity. The invention also relates to pharmaceutical and food compositions containing said peptides and to the preparation methods thereof.

Abstract: The present invention relates to a milk fraction obtainable by acidification of micellar casein and separation from precipitated casein named acid soluble protein from micellar casein. It was found that the milk fraction and especially certain sub-fractions thereof are bioactive and promote GLP-1 release in vitro. Based on these results, acid soluble protein from micellar casein may be useful in the treatment and the prevention of diabetes type II, obesity and may further be added to formulas directed at other purposes addressing the gastro-intestinal tract.

Abstract: In one embodiment, a bioremediation agent and method of bioremediation of an oil spill are disclosed. The bioremediation agent contains oil-digesting bacteria and bacterial nutrients in a buoyant water semi-insoluble and biodegradable casein product. The bioremediation agent may be distributed by boats or seeded by aircraft to remediate oil from coastlines after an oil spill.

Abstract: Complexes comprising resveratrol and a casein, a process for their manufacture, their uses and compositions comprising them.

Abstract: Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.

Abstract: The present invention provides a phosphopeptide or phosphoprotein (PP) stabilized amorphous calcium phosphate or amorphous calcium fluoride phosphate complex having a calcium ion greater than about 30 moles of calcium per mole of PP.

Abstract: This document provides methods and materials for providing teeth with a white appearance. For example, methods and materials for contacting teeth with one or more fluorescence emitting polypeptides (e.g., a blue fluorescent protein (BFP)) to provide the teeth with a whiter appearance are provided.

Abstract: The present invention relates to a method of in vitro isolation of buffalo ?-caesin promoter (buCSN2) along with the regions exon1, intron1 and exon2 from the genomic DNA in vitro (Bubalus bubalis) and its functional activity in using mammary cell line. The novel buffalo ?-caesin promoter along with exon1, intron1 and exon2 is isolated and cloned upstream of the Enhanced Green flourescence protein (EGFP) gene and sequenced. The transfection of the DNA construct resulted into production of EGFP protein in mammary cell lines, confirming bioactivity of this newly isolated buffalo promoter sequence. More specifically, the present invention relates to isolation, cloning, sequencing and functional analysis of the buffalo ?-casein promoter in vitro using mammary cell line.

Abstract: A method for detecting adrenocorticotropic hormone comprising: bringing a liquid sample containing adrenocorticotropic hormone into contact with gelled casein to adsorb adrenocorticotropic hormone to the gelled casein; and detecting the adrenocorticotropic hormone adsorbed to the gelled casein is disclosed. An adsorbent of adrenocorticotropic hormone comprising gelled casein is also disclosed.

Abstract: The present invention refers to an iron (III) caseinsuccinylate characterised by a content of iron comprised between 4.5% and 7% by weight, and by a solubility in water approximately greater than 92%. The present invention further refers to a method for preparing iron (III) caseinsuccinylate.

Abstract: An inhibitor against the formation of biofilm includes ?-casein macropeptide. The inhibitor prevents or reduces the formation of a biofilm by inhibiting attachment or attachment/invasion followed by biofilm formation on the abiotic or biotic surfaces by L. monocytogenes. The inhibitor can be applied as a food or pharmaceutical additive, a detergent for food or equipments for manufacturing food or pharmaceutics as well as a packing material for food or pharmaceutics.

Abstract: This document provides methods and materials for providing teeth with a white appearance. For example, methods and materials for contacting teeth with one or more fluorescence emitting polypeptides (e.g., a blue fluorescent protein (BFP)) to provide the teeth with a whiter appearance are provided.

Abstract: The invention relates to the production of bioactive products that are derived from milk proteins for the production of bioactive milk products derived from milk proteins, particularly caseins. The 16 inventive peptides can be obtained chemically, biotechnologically or by means of enzymatic treatment from proteins containing same and give rise to peptides with an antimicrobial activity, an in vitro angiotensin converter inhibitor activity and/or antihypertensive activity and/or antioxidant activity. Said nutraceutical products are suitable for use in the food and pharmaceutical industries, both in the form of a hydrolyzate or bioactive peptides.

Abstract: The present invention provides a test device for indicating the presence, concentration and effectiveness of chemical and biological agents. The test device interacts with the target agent producing a detectable signal indicating the presence, concentration and effectiveness of the agent.

Abstract: A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a patch. The ratio between the aldehyde and the amino acid containing species is between 20:1 and 1:1 on an aldehyde moiety:amino acid or peptide subunit molar basis. Particularly strong seals are formed when the protein and cross-linking agent are present in a molar ratio of between 15:1 and 1:1.

Abstract: The subject invention provides novel devices and methods for the detection of the presence and/or activity of proteases in biological samples

Abstract: An inhibitor against the formation of biofilm includes ?-casein macropeptide. The inhibitor prevents or reduces the formation of a biofilm by inhibiting attachment or attachment/invasion followed by biofilm formation on the abiotic or biotic surfaces by L. monocytogenes. The inhibitor can be applied as a food or pharmaceutical additive, a detergent for food or equipments for manufacturing food or pharmaceutics as well as a packing material for food or pharmaceutics.

Abstract: The present invention relates to novel antimicrobial composition comprising a peptide which can be obtained from the milk protein casein or chemically synthesised or produced by recombinant DNA technology and a divalent cation.

Abstract: A process to produce IPP from a protein source whereby the protein source comprises a protein having the -I-P-P- sequence and having in the protein amino acid sequence at least 6 times more -I-P-P- present than -V-P-P- (molar basis) which comprises hydrolysing the protein source to liberate at least 40% of the I-P-P- sequence into the peptide IPP and whereby a proteolytic enzyme is used which cleaves at the carboxy-terminus of proline residues present in the protein source, the enzyme is preferably a proline specific endoprotease or proline specific oligopeptidase, more preferably a proline specific endoprotease, and optionally an amino peptidase.

Abstract: A method for precipitating casein from a suspension comprising milk is disclosed. The method includes the following steps: adding a phosphate solution to a suspension; mixing the phosphate solution with the suspension to form a mixture having a phosphate concentration greater or equal to 40 mM; freezing the mixture having a phosphate concentration greater or equal to 40 mM to obtain a frozen mixture; and thawing the frozen mixture to obtain casein-containing aggregates in the mixture, in which the phosphate solution is buffered at a pH value of no less than 4.4.

Abstract: The present invention relates to the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for combating (i.e. helping to prevent, inhibit and/or treat) dental erosion and/or tooth wear caused by subsequent exposure to acid.

Abstract: The present invention provides a film composition effective for correcting irregularities on the skin surface, which has stretchability and flexibility as a result of crosslinkable protein microparticles in the film composition being crosslinked by transglutaminase, as well as superior air permeability and moisture evaporation properties as a result of forming a film with the crosslinkable protein microparticles.

Abstract: An immobilization method for immobilizing a physiologically active substance on a solid phase carrier, the method including: bringing the solid phase carrier into contact with an acid anhydride functional group-containing silane coupling agent represented by the following Formula (I); and carrying out a process of binding of the physiologically active substance to the acid anhydride functional group while maintaining the solid phase carrier after the contact at a temperature within the range of 0° C. to 60° C.; a physiologically active substance-immobilized carrier, and a carrier for immobilization are provided. Further, a carrier including a porous material treated with an acid anhydride functional group-containing silane coupling agent represented by the following Formula (I), a blocking agent that is immobilized to the porous material; and a method for producing it is provided.

Abstract: It is an object of the present invention to provide a method for chemically modifying biopolymer and polypeptide with a hydrophobic compound or a compound which causes degradation or reaction under basic condition. The present invention provides a method for producing a chemically modified biopolymer or polypeptide, wherein a biopolymer or polypeptide is chemically modified in a reaction solution containing an organic fluorine compound.

Abstract: Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the oS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases.

Abstract: It is an object of the present invention to provide: a positively charged nanoparticle which can be produced without using surfactants or synthetic polymers, the size of which can be controlled, which is stable at acidic condition, and which contains an active substance therein; and a method for producing the same. The present invention provides a casein particle, wherein zeta potential is positive.

Abstract: The present invention relates to a milk fraction obtainable by acidification of micellar casein and separation from precipitated casein named acid soluble protein from micellar casein. It was found that the milk fraction and especially certain sub-fractions thereof are bioactive and promote GLP-1 release in vitro. Based on these results, acid soluble protein from micellar casein may be useful in the treatment and the prevention of diabetes type II, obesity and may further be added to formulas directed at other purposes addressing the gastro-intestinal tract.

Abstract: Complexes comprising resveratrol and a casein, a process for their manufacture, their uses and compositions comprising them.

Abstract: Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the ?S1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases, alone or in combination with other peptides or blood cell stimulating factors.

Abstract: The present invention relates to the field of food technology and delivery of hydrophobic biologically active compounds, particularly nutrients, via food products and beverages. In particular the present invention provides isolated casein micelles useful for the encapsulation of hydrophobic nutrients, therapeutic and cosmetic compounds, compositions thereof and methods of preparing the micelles.

Abstract: The present application provides dental fillers, and methods of making and using dental fillers that include a treated surface that includes a caseinate. Dental compositions including such dental fillers can be useful for delivering ions to the oral environment. Dental compositions, and methods of using dental compositions that include a caseinate and a hardenable resin or a water-dispersible, polymeric film former are also provided.

Abstract: The present invention relates to a milk fraction obtainable by acidification of micellar casein and separation from precipitated casein named acid soluble protein from micellar casein. It was found that the milk fraction and especially certain sub-fractions thereof are bioactive and promote GLP-1 release in vitro. Based on these results, acid soluble protein from micellar casein may be useful in the treatment and the prevention of diabetes type II, obesity and may further be added to formulas directed at other purposes addressing the gastro-intestinal tract.

Abstract: There is provided an agent having at least one of an improving effect on vascular endothelial functions and an inhibitory effect on vascular intimal thickening, as well as a prophylactic of arteriosclerosis, which have excellent safety, improve functions associated with the vascular endothelium, have effects of preventing various diseases associated with vascular endothelial functions and of inhibiting vascular intimal thickening, and may be expected to provide prophylactic effect on arteriosclerosis or the like. The agents of the present invention contain, as an active component: (a) Xaa-Pro-Pro, (b) a hydrolysate of animal milk casein containing Xaa-Pro-Pro, or a concentrate thereof, or (c) a fermentation product containing Ile-Pro-Pro and/or Val-Pro-Pro obtained by fermenting a starting material containing milk protein with a bacterial strain of the species Lactobacillus helveticus.

Abstract: The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEA?PEVIESPPE (SEQ ID NO:3), AVESTVATLED?PEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.

Abstract: The invention provides, in one aspect, compositions for delivering a bioactive metal ion to a mammal, the compositions comprising (a) an effective amount of a source of the bioactive metal ion, (b) a phosphoprotein preparation obtained by partially cross linking a partial hydrolysate of casein or a caseinate, and (c) one or more physiologically acceptable diluents or carriers. Also provided are compositions for remineralising tooth enamel and/or for treating or preventing dental caries, tooth erosion, dentinal hypersensitivity or gingivitis in a mammal, wherein the compositions comprise an effective amount of such a phosphoprotein preparation, in combination with one or more carriers or diluents. In related aspects, the invention provides methods of using such compositions. Also provided are novel phosphoprotein preparations suitable for use in such compositions and methods.

Abstract: I provide a non-toxic protein and protein compound conversion coated metal article, a painted or plated non-toxic protein and protein compound conversion coated metal article, the aqueous coating solution to provide the in-situ conversion protective coating, and a process of preparing the article. The article is a metal selected from the group consisting of aluminum and aluminum alloy. The solution has a pH of 3.0 to 12.0 and preferably 4.0 to 10.0 and a protein and protein compound concentration of 0.1 to 10% by weight and the protein and protein compound have a molecular mass of 16,700 to 1,000,000.

Abstract: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing ?-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein ?-casein accounts for 60% by mass or more of the milk-derived casein.

Abstract: Phosphopeptides containing the Ser(P) cluster sequence motif Ser(P)-Ser(P)-Ser(P)-Glu-Glu- can stabilize their own weight in amorphous calcium phosphate (ACP) [Ca3(PO4)1.87(HPO4)0.2xH2O] and amorphous calcium fluoride phosphate (ACFP) [Ca8(PO4)5F x H2O]. The amorphous phases stabilised by the phosphopeptides are an excellent delivery vehicle to co-localise Ca, F, and phosphate at the tooth surface in a slow-release amorphous form producing superior anticaries efficacy. These amorphous phases stabilised by the phosphopeptides also have utility as dietary supplements to increase calcium bioavailability and to help prevent diseases associated with calcium deficiencies.

Abstract: The present invention relates to the use of alpha-lactalbumin in the preparation of preparations to be used in therapeutic or prophylactic treatment and/or for diagnostic use for infections, preferably of the respiratory tract, caused by bacteria, in particular S. pneumoniae and/or H. influenzae. The present invention further relates to essentially pure protein complexes comprising alpha-lactalbumin and the use of these protein complexes for therapeutically or prophylactically treating a bacterial infection, especially infections of the respiratory tract caused by S. pneumoniae and/or H. influenzae.

Abstract: A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a patch. The ratio between the aldehyde and the amino acid containing species is between 20:1 and 1:1 on an aldehyde moiety:amino acid or peptide subunit molar basis. Particularly strong seals are formed when the protein and cross-linking agent are present in a molar ratio of between 15:1 and 1:1.

Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.